ZIOPHARM Oncology Inc (ZIOP) News

ZIOPHARM Oncology Inc (ZIOP): $0.87

0.01 (-0.88%)

POWR Rating

Component Grades








Add ZIOP to Watchlist
Sign Up

Industry: Biotech




#348 of 455

in industry

Filter ZIOP News Items

ZIOP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ZIOP News Highlights

  • ZIOP's 30 day story count now stands at 4.
  • Over the past 7 days, the trend for ZIOP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ZIOP are FORD.

Latest ZIOP News From Around the Web

Below are the latest news stories about Ziopharm Oncology Inc that investors may wish to consider to help them evaluate ZIOP as an investment opportunity.

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evaluable TCRs to 10, further expanding number of eligible patientsIn-house cGMP manufacturing facility is operational to support internal clinical development programsCompany changes name to Alaunos Therapeutics reflecting renewed

Yahoo | January 26, 2022

Allred Capital Management, LLC Buys Tractor Supply Co, Equifax Inc, NextEra Energy Inc, Sells ...

Investment company Allred Capital Management, LLC (Current Portfolio) buys Tractor Supply Co, Equifax Inc, NextEra Energy Inc, Newmont Corp, Paychex Inc, sells iShares S&P 500 Growth ETF, Vanguard Total Bond Market ETF, Ford Motor Co, Adobe Inc, AT&T Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Allred Capital Management, LLC.

Yahoo | January 25, 2022

Is ZIOPHARM Oncology (NASDAQ:ZIOP) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | January 21, 2022

Why Ziopharm Oncology Shares Rose 10.5% on Wednesday

The clinical-stage biopharmaceutical company is examining non-viral T-cell receptor therapies (TCR-T) to fight cancer. There are two reasons for Ziopharm's climb. First, it's a reaction to hitting its 52-week low as investors saw a potential bargain.

Yahoo | January 19, 2022

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Expected to Post Earnings of -$0.09 Per Share

Equities analysts expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report earnings of ($0.09) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ZIOPHARM Oncologys earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.11). ZIOPHARM Oncology reported earnings of ($0.11) per share during the same []

Dakota Financial News | December 19, 2021

Gateway Advisory LLC Buys Shares of 15,301 ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)

Gateway Advisory LLC bought a new stake in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,301 shares of the biotechnology companys stock, valued at approximately $28,000. Other large investors also recently added []

Transcript Daily | December 6, 2021

Zacks: Brokerages Expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to Announce -$0.09 EPS

Brokerages expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to announce earnings of ($0.09) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for ZIOPHARM Oncology’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.07). ZIOPHARM Oncology reported earnings of ($0.11) per share in […]

Dakota Financial News | December 6, 2021

ECMOHO Limited Announces the Appointment of independent director of the Board

SHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), an integrated solutions provider in the health and wellness market in China, today announced a change in its board of directors (the “Board”). Mr. Greg Ye tendered to the Board his resignation as an independent director of the Board, the chair and a member of the audit committee of the Board and a member of the Nominating and Corporate Governance Committee of the Board for personal reaso

Yahoo | December 6, 2021

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Stake Boosted by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD increased its holdings in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) by 8.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 102,936 shares of the biotechnology companys stock after purchasing an additional 8,331 shares during the quarter. Price T Rowe Associates Inc. MDs holdings in ZIOPHARM Oncology were worth $272,000 []

Dakota Financial News | December 4, 2021

ZIOPHARM Oncology (NASDAQ:ZIOP) Rating Reiterated by HC Wainwright

ZIOPHARM Oncology (NASDAQ:ZIOP)s stock had its hold rating reissued by analysts at HC Wainwright in a report issued on Monday, Price Targets.com reports. Several other equities research analysts have also weighed in on the company. Lake Street Capital cut their target price on ZIOPHARM Oncology from $7.00 to $3.50 and set a buy rating on []

Transcript Daily | November 24, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!